



CLEARPOINT[®]
NEURO

WHEN YOUR PATH IS UNCLEAR,
WE POINT THE WAY.

Nasdaq: CLPT
August 2026





DISCLAIMER

FORWARD-LOOKING STATEMENTS

Statements in this presentation and discussion concerning ClearPoint Neuro's (the "Company's") plans, growth, and strategies may include forward-looking statements within the meaning of the federal securities laws. Statements regarding the Company's future events, developments and future performance; the continued development, anticipated timing, and potential commercial opportunity of the Company's pipeline of products and services under development, including its proprietary Robotic Neuro-Navigation System, Focused Ultrasound System, cell and gene therapy delivery devices and routes of administration, software modeling and navigation tools, and preclinical service capabilities; the anticipated timing, scope, cost and completion of the build-out, equipping, validation and qualification of the ClearPoint Advanced Laboratories facility, and the anticipated timing, performance and revenue contribution of preclinical, GLP and other services to be provided there; the expected future role of the Company's products and services in addressing unmet needs in neurological diseases and the potential market opportunity for therapies targeting those indications; the Company's belief about the outcome of regulatory interactions with respect to its biotech Partners' therapies, the benefits of regulatory expedited review with respect to accelerating the timing of commercialization of such therapies, and the market potential for such therapies; the size of total addressable markets or the market opportunity for the Company's products and services, including for the Prism Laser Therapy System; the Company's preclinical CRO facility, the IRRAS/flow Active Fluid Exchange System, and the Company's navigation technology; the anticipated adoption of the Company's products and services for use in the delivery of gene and cell therapies; the Company's ability to scale its operations, commercialization, and increase utilization of its products in neurosurgical centers; the Company's 4-Pillar Product pipeline; the Company's future looking 4-phase strategy; the Company's four and five pillar growth strategy for 2026 and beyond; the Company's expectations for revenues, including its revised revenue guidance for the year ending December 31, 2026, market share, operating expenses, and management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws.

RISK FACTORS

These forward-looking statements are based on management's current expectations and are subject to the risks inherent in the business, which may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the Company's biotech Partners' risks related to the ongoing conduct of their clinical studies, including the risk that such trials will be unable to demonstrate data sufficient to support further clinical development or regulatory approval; the risk that more patient data becomes available that results in a different interpretation than the data already released for gene and cell therapies; risks related to interactions with regulatory authorities, which may affect the initiation, timing and progress of clinical trials and pathways to regulatory approval of the biotech Partners' therapies; the limitation or modification of the FDA's eligibility and criteria for its expedited review programs with respect to such therapies; the commercialization and acceptance of gene and cell therapies; the Company's biotech Partners' continued use of the Company's products and services in their delivery of gene and cell therapies; the Company's ability to maintain its current relationships with its biotech Partners or enter into relationships with new partners; the Company's ability to continue to build and maintain the infrastructure and personnel needed to allow for widespread adoption of intracranial administration of gene and cell therapies; the Company's ability to recruit, hire, train and retain qualified clinical specialists and other personnel on the timeline and in the geographies necessary to support its partners' clinical and potential commercial programs, and the

costs of doing so; risks inherent in the research, development, and regulatory approval of the Company's new pipeline products and the Company's ability to continue funding of such research, development, and regulatory approval; the future market for preclinical services and the investment required to expand such services, which could divert resources from the Company's other business operations; risks relating to the Company's leased laboratory facility, including delays or cost overruns in construction, build-out, equipment delivery, installation, validation or qualification, the condition and habitability of the leased premises, and the risk that GLP or other service capabilities are not established, or do not generate revenue, when expected or at all; risks relating to the Company's collaborations with academic and other third-party institutions, including with respect to focused ultrasound, such as the risk that such collaborations do not produce commercially viable technology, that the parties disagree as to the terms of the collaboration, or that such arrangements are terminated or modified; the possibility that the anticipated benefits of the IRRAS transaction are not realized when expected or at all; the Company's failure to integrate IRRAS into its business in accordance with expectations; deviations from the expected market potential of the IRRAS products; diversion of management's attention and resources in connection with the integration of IRRAS; macroeconomic and inflationary conditions; regulatory and policy uncertainty; the introduction of or changes in tariffs, sanctions, or trade barriers; changes in monetary policy; geopolitical trends, such as instability, protectionism and economic nationalism; the Company's ability to market, commercialize and achieve broader market acceptance for new products and services offered by the Company; the risk that the Company does not achieve its revenue guidance or other financial expectations for 2026 or future periods; the availability of additional funding to support the Company's research and development programs and commercialization efforts; the ability of the Company to manage the growth of its business; and the Company's ability to attract and retain its key employees.

THIRD PARTY INFORMATION



This presentation contains information concerning the Company's biotech Partners and their product candidates and clinical and regulatory programs, as well as market, industry, prevalence, cost and ranking data attributed to third parties. That information is derived from the Partners' own public disclosures and from other publicly available sources. The Company has not independently verified such information, does not adopt or endorse it, and undertakes no obligation to update it. Statements regarding the Partners' plans, expectations, submissions or timelines are the statements of those third parties and not of the Company.

PRODUCT STATUS

Certain products and product features described in this presentation are in development and are not cleared or approved for commercial distribution in any jurisdiction. Products that are cleared or approved are not cleared or approved in all territories or for all indications described.

For a detailed description of the Company's risks and uncertainties, you are encouraged to review its documents filed with the SEC including the Company's recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Biologics and Drug Delivery



CLEARPOINT[®] NEURO


OUR COMPANY

We Enable Delivery of Both Drug and Device Therapies by Offering Precise Navigation to the Brain and Spine

Our Unique Platform Includes Proven Clinical Products Used by Hospitals and Neurosurgeons, and Drug Development Services Used by BioPharma Partners



Neuro Navigation
and Robotics*



Ablation Therapy
and Access



Neurocritical Care
Management


*Robotic product is in development phase. Commercialization is subject to successful development, testing, and applicable regulatory clearance.



The Future of Neuro Biologics and Drug Delivery is Here Today

More than **30 Million people** in the U.S. alone are estimated to suffer from **severe and debilitating neurological disorders.**

Neurological diseases cost Americans nearly \$800 Billion annually. To reduce these costs, we must improve both the therapies and the access to care.



30 Million Patients Indicated in the U.S.



30 Million Patients

U.S. prevalence pool


<300k treated to date with
minimally-invasive neurosurgery
<1% penetration

ClearPoint Neuro believes that biologics and drug delivery, including cell and gene therapies, will be the answer, and that our minimally invasive tools will make these therapies accessible.



The Future of Neuro Biologics and Drug Delivery is **Here Today**

Of those 30 million patients, 2.1 million in the U.S. alone have disorders where a ClearPoint BioPharma Partner has already been accepted for FDA expedited review.



Parkinson's Disease (1.0m)
Drug Resistant Epilepsy (1.0m)
Frontotemporal Dementia (60k)
Huntington's Disease (41k)
Glioblastoma (22k)
Friedreich's Ataxia (5k)
AADC Deficiency (rare)
Hunter Syndrome (rare)



ClearPoint Neuro has 60+ Active Pharma Partners, with 10+ programs accepted for FDA expedited review. In 2024, the first gene therapy delivered directly to the brain was approved.

FDA NEWS RELEASE

FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

For Immediate Release: November 14, 2024

The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency.

Importantly, this gene therapy is labeled as a **combination product** with the ClearPoint SmartFlow Neuro Cannula

The FDA also authorized the SmartFlow Neuro Cannula, an infusion tube inserted into a target in the brain (parenchymal tissue), to deliver Kebilidi. The SmartFlow Neuro Cannula is currently the only FDA authorized device indicated for use to administer Kebilidi. The FDA granted authorization of the SmartFlow Neuro Cannula to ClearPoint Neuro, Inc.



Our Company

Our 4-Phase Strategy Positions ClearPoint for Decades of Growth

2010 - 2019



1

DESIGN. DISCOVERY.

EXTEND OUR LEAD WITH A
UNIQUE DRUG DELIVERY
ECOSYSTEM DESIGNED FOR
CELL AND GENE THERAPY

Our one-of-a-kind drug delivery platform including neuro navigation, predictive modeling, co-labeled delivery devices, infusion monitoring software and expert clinical case support has become the leading choice by biopharma developers

2020 - 2025



2

FUNDED. FOUNDATION.

GROW OUR ACTIVE INSTALLED
BASE OF 150+ LEADING GLOBAL
INSTITUTIONS AND ADD
PROCEDURAL CAPACITY

With more than \$100m of capital invested over the past 5 years, our large commercial footprint, rapidly expanding installed base, high-capacity manufacturing, stress-tested quality system, global regulatory reach and expansive IP portfolio has given us a mature foundation on which to build

2026+



3

FAST. FORWARD.

LEVERAGE OUR EXISTING
PORTFOLIO TO PENETRATE
A \$1B EXISTING MARKET
OPPORTUNITY TODAY

Our current products and pipeline, combined with our growing commercial reach will continue to compete in these four existing markets;

- 1) Biologics & drug delivery,
- 2) Neuro navigation & robotics,
- 3) Ablation therapy and access,
- 4) Neurocritical management,

Our next goal is to earn 20% share, generate \$200m in annual revenue

2026+



4

ESSENTIAL. EVERYWHERE.

BUILD A NEW \$10B MARKET
ALONGSIDE OUR 60+
BIOPHARMA PARTNERS AND
DIVERSIFIED ACROSS 15+
INDICATIONS THAT INCLUDES
DRUGS THAT ARE CO-LABELED
WITH CLEARPOINT
TECHNOLOGY

More than 10 of our partners have now been accepted for FDA expedited review and are leveraging our unique ecosystem, clinical trial experience, and proven global regulatory leadership

Our next goal is to treat just 1% of patients with these indications under expedited review, generate another \$300m in annual revenue




Design. Discovery.

The Unique ClearPoint Ecosystem Has Been Years in the Making

ClearPoint Neuro embraced the unmet need in neuro biologics and drug delivery, and has **invested more than \$200m over the past 15 years** to build a substantial headstart and leadership position.

This expansive platform has been used in more than **10,000 procedures to date** and has regulatory approvals across **34 countries and counting**.*

We are positioned to benefit from the expanded use of our delivery platform to include future cell and gene therapies, new DBS and BCI indications, second generation laser ablation therapy, and more advanced approaches to neurocritical fluid management.







Funded. Foundation.

Our Installed Base Has Grown to More than 175 Active Global Centers

Over 160 employees worldwide focused exclusively on Neuro



● Active ClearPoint Installation
(Additional Sites in Asia, EMEA, LATAM)



~50% of the Top Ranked Neurosurgery Programs use ClearPoint Technology

US News & World Report Best Neurology/Neurosurgery Hospitals 2025-2026
are recognized for excelling in the treatment of complex, high-risk neurological specialty cases.

Evaluation Criteria

45% Outcomes

35% Structure

12% Process / Expert Opinion

5% Patient Experience

3% Public Transparency

- UCSF Medical Center
- New York-Presbyterian Hospital-Columbia and Cornell
- Rush University Medical Center
- Northwestern Memorial Hospital
- Johns Hopkins Hospital
- Hospital of University Pennsylvania
- UT Southwestern Medical Ctr
- Massachusetts General Hospital
- Stanford Health Hospital
- Cleveland Clinic
- UCLA Medical Center
- Houston Methodist Hospital
- Brigham & Women's Hospital
- Barnes-Jewish Hospital
- Cedars-Sinai Medical Center
- Mayo Clinic Arizona
- Mayo Clinic Florida
- Advent Health Orlando
- Keck Medical Center of USC
- Thomas Jefferson University
- UC Davis Medical Center
- UCSD Jacobs Medical Center
- University of Michigan
- Mount Sinai West
- University of Kansas
- Emory University Hospital
- Hackensack Meridian Health
- Corewell Beaumont University
- Yale University Hospital
- Ohio State University – Wexner
- University of Alabama at Birmingham
- University of Minnesota
- Barrow Institute
- Duke University Hospital
- University of Wisconsin, Madison
- Tampa General Hospital
- UC Irvine Medical Center
- Baptist Health Miami Hospital
- Ochsner Medical Center
- Penn State Health Milton
- Inova Fairfax Hospital
- Oregon Health & Science University
- University of Colorado Aurora
- Henry Ford Health
- University of North Carolina
- Froedtert Hospital
- Ohio Health Riverside
- University of Utah
- Georgetown University



Funded. Foundation.

Stress-Tested QMS and Operations

We have invested in our Research & Development, Quality, and Manufacturing infrastructure to build confidence for both hospitals and biopharma partners

We bring **medical device expertise and regulatory combination product acumen** to pharmaceutical companies

ClearPoint Neuro assets available to our partners:

- ❖ HQ & training facility in Solana Beach, CA
- ❖ Advanced Research Laboratory in Torrey Pines, CA
- ❖ R&D and manufacturing facility in Carlsbad, CA
- ❖ ISO 13485 / MDSAP / EU MDR certified QMS
- ❖ Proven audit history with pharma partners, FDA and global regulatory body inspections





Funded. Foundation.

Growth Continues Today While We Prepare for Commercial Drug Approvals

HEADQUARTERS

Solana Beach, CA

R&D, MANUFACTURING

Carlsbad, CA

ADVANCED RESEARCH LABORATORIES

Torrey Pines, CA

2025 REVENUE

\$37.0m^(A)

GROSS MARGIN

63%^(B)

PATENTS ISSUED


130+^(C)

CASH & CASH EQUIVALENTS

\$29.4m^(D)

EMPLOYEES

160+



(A) For the year ended December 31, 2025
(B) Unaudited, for the trailing twelve months ended June 30, 2026
(C) Including owned and licensed patents
(D) Unaudited, as of, and for the quarter ended June 30, 2026



Funded. Foundation.

Experienced Leadership in Place

EXECUTIVE LEADERSHIP TEAM

Proven industry operators with decades of experience in medical devices, biopharmaceuticals, and clinical research.



Joe Burnett

President &
Chief Executive Officer



Danilo D'Alessandro

Chief Financial
Officer



Jeremy Stigall

Chief Business
Officer



Mazin Sabra

Chief Operating
Officer



Paul Larson, MD

Chief Medical
Officer



Elisa Cholapranee

General
Counsel



Megan Faulkenberry

Senior Vice President
of Quality



Rob Korn

Senior Vice President
of Sales



Mary McNamara-Cullinane

Senior Vice President
of Regulatory Affairs



Tim Orr

Vice President of
Software Development



Lyubomir Zagorchev, PhD

Vice President of Clinical
Science & Applications



Ernesto Salegio, PhD

Senior Vice President of Translational
& Pre-Clinical Research



Fast. Forward.

Our 4-Pillar Growth Strategy



FAST. FORWARD.

Our **Fast. Forward.** 4-Pillar Growth Strategy is to **Win 20% of an Existing \$1.0B Global Market Opportunity, Generate \$200m in Annual Revenue, and to Achieve Cash Breakeven and Profitability Along the Way**

Collective \$1.0B Existing Market Opportunity Today

\$300m+

Existing Market

 **CLEARPOINT**
ADVANCED LABORATORIES

Pre-Commercial
Biologics &
Drug Delivery

\$125m+

Existing Market

CLEARPOINT
NAVIGATION SYSTEM

Neurosurgery
Navigation
& Robotics

\$75m+

Existing Market

 **CLEARPOINT**
PRISM
NEURO LASER THERAPY SYSTEM

Laser Ablation
Therapy
& Access

\$500m+

Existing Market

IRRAflow[®]

Neurocritical Care
& Active CSF
Exchange

Increasing Global Scale with Clearances in 34 Countries Worldwide*

*Not all products cleared or approved in all territories.

© 2026 CLEARPOINT NEURO



Fast. Forward.

Pillar 1: Pre-Commercial Biologics & Drug Delivery

ClearPoint Neuro currently offers a boutique, neuro-focused CRO complete with device co-development services, pre-clinical testing capabilities, and validated clinical trial products to support and de-risk our more than 60 active pharma partners, and generate revenue before reaching the drug commercialization stage.

 **CLEARPOINT**
ADVANCED LABORATORIES

**Pre-Commercial
Biologics &
Drug Delivery**

\$300m+
Existing Market

Combining Services & Technology

Benchtop Testing



- Device compatibility testing
- Custom device development
- Delivery system validation
- Performance assessment

Preclinical Studies




- Running preclinical studies
- Surgical planning & strategy
- Dosing & surgical expertise
- Post-procedure analysis

Hardware



Leverage Both
Commercial and In-Development
Delivery and Navigation Tools

Software



SmartFlow Software & Biophysical
Modeling in Collaboration with
NE Scientific



Fast. Forward.

Pillar 2: Neuro Navigation & Robotics


ClearPoint will provide unmatched flexibility by having a single pre-planning software offering several workflows deployed via either MRI, iCT and eventually, Robotics. This strategy balances the consistency of delivery that biopharma partners desire with the optionality and adaptability for surgeons to choose their desired technique.

CLEARPOINT
NAVIGATION SYSTEM

Neurosurgery
Navigation
& Robotics

\$125m+
Existing Market

Pre-Planning & Navigation Software



◀ Choose a Workflow



PLAN

MRI



CT



ROBOT



Select Optimal Delivery Method



SmartFrame XG
with iCT or MRI-guidance



ClearPoint Robotic
Platform using
the KUKA LBR
Robotic Arm



Focused
Ultrasound

*Focused Ultrasound and Robotic product is in development phase. Commercialization is subject to successful development, testing, and applicable regulatory clearance.



Fast. Forward.

Pillar 3: Laser Therapy & Access

ClearPoint Prism is a mobile laser therapy system featuring innovative non-cooled applicator technology that simplifies setup, reduces power and potentially ablation time, and enables efficient workflows. Surgeons can capitalize on workflow efficiency and total system accuracy when Prism is combined with ClearPoint Navigation.

The Velocity^{ALPHA} MR High Speed Surgical Drill System is a versatile cutter system designed to reduce procedure times in both the MRI suite and the operating room.



Laser Ablation
Therapy
& Access

\$75m+
Existing Market



With Optional ClearPoint Navigation Synergies



One Room



One System



One Team

Velocity^{ALPHA} MRI Conditional Power Drill

A Versatile Power Solution for SmartFrame in the MRI and OR





Fast. Forward.

Pillar 4: Neurocritical Management

ClearPoint's recent acquisition of IRRAS expands the portfolio with a unique and disruptive solution for neurocritical care and intracranial fluid management. IRRAf^{low} enables active irrigation and controlled drainage of hemorrhage, toxins, and clots to therapeutically treat intracranial pathologies.


IRRAflow[®]

Neurocritical Care
& Active CSF
Exchange

\$500m+
Existing Market

IRRAflow[®]

Active Fluid Exchange System Components



IRRAflow
Dual-Lumen
Catheter



IRRAflow Tube Set &
Intelligent Digital Cassette



IRRAflow Control Unit
& Drainage Collection Bag



Fast. Forward.

Clear and Continued Investment in ClearPoint's 4-Pillar Product Pipeline

	2026	2027	2028+
1  CLEARPOINT ADVANCED LABORATORIES	✓ Radiopharma Formulation ✓ MRI/CT Imaging Capable ✓ Cell Culture Capability ✓ Radiolabeling Active • Histopathology Active	• GLP Study Capable • Pre-clinical Z-Axis Bolt • Pre-Clinical Focused Ultrasound • PET/SPECT Imaging Live • MRI/CT Installed	• Bioanalytic Lab Active • Pathology Lab Active • Hot Cell F-18 Radiochemistry • Translational Models for tumor, stroke and spinal cord injury
2 CLEARPOINT NAVIGATION SYSTEM	✓ CE Mark for 3.x Software • Global Installed Base with iCT Upgrade • Publication of iCT Real-World Data	• SmartFrame Accessory Kit • Pre-Clinical Robotic System at The CAL • Harmony 1.0 Software • Sub-Nuclei Segmentation	• Harmony 2.0 Software • Robotic System • SmartFrame Duet • DBS/BCI Area of Activation • Non-Rigid Fusion • CM Segmentation
3  CLEARPOINT PRISM NEURO LASER THERAPY SYSTEM	✓ 1.5T Compatibility ✓ Velocity MRI Power Drill • ThermoGuide 3D Damage Model Export	• Harmony 1.0 Therapy Visualization • Philips MRI Compatibility	• CE Mark Prism System • Predictive Ablation Software • 3D Thermal Modeling Study Initiated • Spine LiTT Data Readout
4  IRRAflow	✓ Next Gen Intelligent Cassette	• Cranial Access Bolt Kit • IRRAflow Dart • Shoreline Software • ARCH RCT Data Readout & Publication • IRRAflow 3.0 CE Mark (OUS)	• Subdural Indication • Rapid Evacuation System • Next Gen Catheter • Bedside Navigation System

Our **Fast. Forward.** 4-Pillar Growth Strategy is to **Win 20% of an Existing \$1.0B Global Market Opportunity, Generate \$200m in Annual Revenue, and to Achieve Cash Breakeven and Profitability Along the Way**

NEUROCRITICAL CARE & ACTIVE CSF EXCHANGE

Expand Existing Portfolio Into Multiple New Indications
Launch Shoreline Software, Cranial Bolt, IRRAf^{low} Dart, Next-Gen IRRAf^{low} Catheter and a Subdural Hemorrhage Catheter Kit

4

LASER ABLATION THERAPY & ACCESS

Add Ablation Coverage & AI Predictive Thermal Modeling Software
Launch Velocity MRI Power Drill for Faster Procedure Times

3

NEUROSURGERY NAVIGATION AND ROBOTICS

Expand into the Operating Room w/ 3.0 Software, SmartFrame Duet, and Robotics
Launch Maestro CT, sub-nuclei segmentation, Non-Rigid Fusion, Area-of-Activation Harmony Software

2

PRE-COMMERCIAL BIOLOGICS & DRUG DELIVERY

Expand Neuro Pre-Clinical CRO Services Portfolio and Capacity including larger GLP Study Capability
Expand Partnerships to Include Co-Development, Commercial Pricing, Drug Clinical Milestones & Royalty Based Agreements
Execute on Development Pipeline for Drug Infusion Monitoring/Modeling, Cell Therapy Actuation, Indwelling Catheters and Spinal Routes of Administration

1

2026+



Essential. Everywhere.

What Does it Mean to be **Essential** to the Future of Cell and Gene Therapy?




ESSENTIAL. EVERYWHERE.

It starts by being **unique**.

Our **Essential. Everywhere.** Strategy is to **build a new market from the ground up** where our unique ecosystem plays an essential role and enables 20,000 annual Cell & Gene Therapy procedures.

Our Goal is to create the capacity for 20,000 CGT patients per year and generate an additional \$300m annually.


*Not all products cleared or approved in all territories.






Essential. Everywhere.

Our Unique Ecosystem Will Play An Essential Role in Cell and Gene Therapy



A.I. Derived Patient
and Tissue Specific
Segmentation



Therapy and Patient
Specific Biophysics
Modeling Tools




Comprehensive
Pre-Planning
Navigation Software
Modules



Flexible Options for
Surgeon Selected
Navigation Including
Frames, Robotics



Multiple Biologic Specific
& Co-Labeled
Routes-of-Administration,
including Focused
Ultrasound



Confirmatory
Volumetric Dosing Data
for Quality of Delivery
Documentation


Every Step Fully
Supported by a Team of
30+ Expert Field-Based
Clinical Specialists





Essential. Everywhere.

ClearPoint Neuro Has 60+ Active Pharma Partners, 25+ Active Clinical Trials



...and more than 15 additional programs that are undisclosed and in preclinical development.



Essential. Everywhere.


10+ Programs Are Already Under FDA Expedited Review

Indication	Preclinical	Phase 1/2	Phase 3 / Pre-Comm	Commercialization
Parkinson's (BlueRock) – BRT-DA01				
Parkinson's (AskBio) – AB-1005				
Parkinson's (Kenai) – RNDP-001				
Parkinson's (Aspen) – ANPD001				
Parkinson's – (Undisclosed)				
Parkinson's – (Undisclosed)				
Epilepsy (MTLE) (Neurona) – NRTX-1001				
Frontotemporal Dementia (AviadoBio) – AVB-101				
Friedreich's Ataxia – (Undisclosed)				
Huntington's (uniQure) – AMT-130				
Glioma (Siren) – SRN-101				
AADC Deficiency (PTC) – KEBILIDI / Upstaza				
Hunter Syndrome (REGENXBIO) – RGX121				



Essential. Everywhere.


Building Surgical Experience and Capacity to Prepare for Drug Commercialization



Existing CLPT
Navigation Site



Experienced CLPT Navigation
Site and Participant in
Active CGT Trial



Our **Essential. Everywhere.** Strategy
Expands Our Vision into a 5-Pillar
Growth Strategy Which
Will Include Commercial Drug
Delivery and Highlights Our Path
to Achieving \$500m in Revenue

COMMERCIAL DRUG DELIVERY

Add Capacity for 5,000 cell & gene therapy procedures
Launch Co-Labeled Products with 10+ partners that are
already under FDA Expedited Review across 8 Indications

5

NEUROCRITICAL CARE & ACTIVE CSF EXCHANGE

Expand Existing Portfolio Into Multiple New Indications
Launch Shoreline Software, Cranial Bolt, IRRAf/low Dart,
Next-Gen IRRAf/low Catheter and a Subdural Hemorrhage Catheter Kit

4

LASER ABLATION THERAPY & ACCESS

Add Ablation Coverage & AI Predictive Thermal Modeling Software
Launch Velocity MRI Power Drill for Faster Procedure Times

3

NEUROSURGERY NAVIGATION AND ROBOTICS

Expand into the Operating Room w/ 3.0 Software, SmartFrame Duet, and Robotics
Launch Maestro CT, sub-nuclei segmentation, Non-Rigid Fusion, Area-of-Activation Harmony Software

2

PRE-COMMERCIAL BIOLOGICS & DRUG DELIVERY

Expand Neuro Pre-Clinical CRO Services Portfolio and Capacity including larger GLP Study Capability
Expand Partnerships to Include Co-Development, Commercial Pricing, Drug Clinical Milestones & Royalty Based Agreements
Execute on Development Pipeline for Drug Infusion Monitoring/Modeling, Cell Therapy Actuation, Indwelling Catheters and Spinal Routes of Administration

1

2026+



Our Company

Our 4-Phase Strategy Positions ClearPoint for Decades of Growth

2010 - 2019



1

DESIGN. DISCOVERY.

EXTEND OUR LEAD WITH A
UNIQUE DRUG DELIVERY
ECOSYSTEM DESIGNED FOR
CELL AND GENE THERAPY

Our one-of-a-kind drug delivery platform including neuro navigation, predictive modeling, co-labeled delivery devices, infusion monitoring software and expert clinical case support has become the leading choice by biopharma developers

2020 - 2025



2

FUNDED. FOUNDATION.

GROW OUR ACTIVE INSTALLED
BASE OF 150+ LEADING GLOBAL
INSTITUTIONS AND ADD
PROCEDURAL CAPACITY

With more than \$100m of capital invested over the past 5 years, our large commercial footprint, rapidly expanding installed base, high-capacity manufacturing, stress-tested quality system, global regulatory reach and expansive IP portfolio has given us a mature foundation on which to build

2026+



3

FAST. FORWARD.

LEVERAGE OUR EXISTING
PORTFOLIO TO PENETRATE
A \$1B EXISTING MARKET
OPPORTUNITY TODAY

Our current products and pipeline, combined with our growing commercial reach will continue to compete in these four existing markets;

- 1) Biologics & drug delivery,
- 2) Neuro navigation & robotics,
- 3) Ablation therapy and access,
- 4) Neurocritical management,

Our next goal is to earn 20% share, generate \$200m in annual revenue

2026+



4

ESSENTIAL. EVERYWHERE.

BUILD A NEW \$10B MARKET
ALONGSIDE OUR 60+
BIOPHARMA PARTNERS AND
DIVERSIFIED ACROSS 15+
INDICATIONS THAT INCLUDES
DRUGS THAT ARE CO-LABELED
WITH CLEARPOINT
TECHNOLOGY

More than 10 of our partners have now been accepted for FDA expedited review and are leveraging our unique ecosystem, clinical trial experience, and proven global regulatory leadership

Our next goal is to treat just 1% of patients with these indications under expedited review, generate another \$300m in annual revenue